Worldwide Dysmenorrhea Treatment Market is Estimated to reach US$ 8.40 billion in 2023 and CAGR of approximately 12.28%

Market research future has a half cooked research report on global dysmenorrhea treatment market. The global market for dysmenorrhea treatment market is growing continuously and expected to grow at a CAGR of 12.28 % from 2017 to 2023

Pain during menstruation is known as dysmenorrhea. Increase in incidence of dysmenorrhea, which is attributed to changing lifestyle, addiction to smoking and alcohol, hormonal changes and physical and mental stress, favor the growth of this market. Additionally, lack of awareness regarding reproductive health and increase in first pregnancy age, favor the growth of this market.

Taste the market data and market information presented through more than 45 market data tables and figures spread over 80 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Dysmenorrhea Treatment market Research Report –Global Forecast to 2023.”

Get a sample report at https://www.marketresearchfuture.com/sample_request/727 .

Global Dysmenorrhea Treatment Market Players:

Key players in Dysmenorrhea Treatment market are: Novartis AG (Switzerland), Merck, Inc. (U.S), Bayer Schering Pharma AG (Germany), Abbott Healthcare (U.S), Pfizer, Inc. (U.S). Other players include F. Hoffmann-La Roche Ltd (U.S), Sanofi (U.S), Taj Pharmaceuticals, Ltd (India).

Novartis AG is a multinational pharmaceutical company. It is one of the largest pharmaceutical companies in the world. The company excels in research & development activities in various branches of healthcare using science based innovations and new business approaches. CATAFLAM is a drug for treating primary dysmenorrhea.

Merck Inc. is a largest pharmaceutical company in the world. It manufactures medicines, vaccine and animal health products. The company produce products for key therapeutic areas like oncology, immunology, neuroscience, cardiovascular disease, respiratory disease, infectious disease, and women's health. “Cyclessa” is a drug manufactured by this company for prevention of pregnancy as a method of contraception.

Bayer Schering Pharma is a German chemical, pharmaceutical and Life Science Company. In June 2017, the company announced the launch of “Dan E Fu Kang ointment” for the treatment of menstrual disorders. It established a partnership with Dayima, a women health management platform in India.

Abbott Healthcare is a global healthcare and research company. Flurbiprofen is a non-steroidal anti-inflammatory agent prescribed for pain raising from dysmenorrhea.

Study Objectives:

Main objective of this research is to provide information about the products, their application and their end users

To provide detailed analysis of the market structure along with forecast for the next six years of the various segments and sub-segments of the Dysmenorrhea Treatment market.
To provide insights about factors affecting the market growth.
To analyze the dysmenorrhea treatment market based on various factors- Price Analysis, Supply Chain Analysis, Porters Five Force Analysis etc.
To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific and Middle East and Africa.
To provide country level analysis of the market with respect to the current market size and future prospective.
To provide country level analysis of the market for segments by type, by treatment, by end users and its sub-segments.
To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.
To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Dysmenorrhea Treatment market.

Browse Complete Report at https://www.marketresearchfuture.com/reports/dysmenorrhea-treatment-market-727 .

Global dysmenorrhea treatment market has been segmented on the basis of type which includes primary dysmenorrhea and secondary dysmenorrhea. Secondary dysmenorrhea has sub-segments namely endometriosis, adenomyosis, uterine myomas, endometrial polyps, cervical stenosis, and obstructive malformations of genital tract. On the basis of treatment the market is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), hormonal, and combined oral contraceptive. End users are hospitals and clinics, diagnostic centers, pharmaceutical companies and others.

Global Dysmenorrhea Treatment market has been segmented on the basis of Type which includes Primary Dysmenorrhea and Secondary Dysmenorrhea. Secondary Dysmenorrhea has sub-segments namely Endometriosis, Adenomyosis, Uterine myomas, Endometrial polyps, Cervical stenosis, Obstructive malformations of genital tract. On the basis of treatment the market is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), hormonal, and combined oral contraceptive. End users are hospitals and clinics, diagnostic centers, pharmaceutical companies and others.

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us
Market Research Future
Maharashtra, India
+1 646 845 9312
Email: sales@Marketresearchfuture.Com

This release was published on openPR.